#IonisPharmaceuticals hashtag - Bluesky

@hdfcures.bsky.social

6 months ago

Watch anytime! Our $1m Transformative Research Award recipients are pursuing innovative strategies to target the triggers of HD & open new pathways for potential treatments. Learn more: hdfoundation.org/webinars-eve...

Thanks to our sponsors, #IonisPharmaceuticals #ClevelandClinic #Novartis #Rgenta

0 0 0 0

Huntington's Disease Foundation

@hdfcures.bsky.social

6 months ago

Researchers have discovered genetic "messages" that may appear only when HD is active. Would silencing these messages stop HD? Learn more on Wed, 9/17, 12-1pm ET. Register: tinyurl.com/9-2025-webinar
Thanks to our sponsors, #IonisPharmaceuticals #ClevelandClinic #Novartis #Rgenta #researchspotlight

1 0 0 0

Huntington's Disease Foundation

@hdfcures.bsky.social

7 months ago

HDF 2024 Transformative Research Award winners uncovered 2 genetic clues only in people with HD with treatment potential. Learn more on Wed, 9/17, 12-1pm ET.
Register: tinyurl.com/9-2025-webinar
Thanks to our sponsors, #IonisPharmaceuticals #ClevelandClinic #Novartis #Rgenta #researchspotlight

0 0 0 0

Huntington's Disease Foundation

@hdfcures.bsky.social

7 months ago

Our $1m Transformative Research Award winners think beyond the htt gene by targeting new molecules that may drive the disease. Learn more on Wed, 9/17, 12-1pm ET.
Register: tinyurl.com/9-2025-webinar
Thanks to our sponsors, #IonisPharmaceuticals #ClevelandClinic #Novartis #Rgenta #researchspotlight

0 0 0 0

Huntington's Disease Foundation

@hdfcures.bsky.social

7 months ago

Can we treat HD by targeting its triggers? Join us on Wed, 9/17, 12-1pm ET to find out!
Webinar with Drs. Andrew Yoo & Osama Al Dalahmah. Live Q&A to follow.
Register: us06web.zoom.us/.../651.../W...
Thanks to our sponsors, #IonisPharmaceuticals #ClevelandClinic #Novartis #Rgenta #researchspotlight

0 0 0 0

Profit Trading USA

@profittradingusa.bsky.social

7 months ago

US FDA approves Ionis’ drug for rare genetic disorder By Sneha S K and Bageshri Banerjee (Reuters) -The U.S. Food and Drug Administration on Thursday approved Ionis Pharmaceuticals (NASDAQ:IONS)’ drug to prevent instances of severe swelling in various parts of the body of patients with a rare genetic disorder. Shares of the company were up 1.1% in afternoon trading. The drug, Dawnzera, is approved as a so-called "prophylaxis" to prevent symptoms of a rare genetic disease called hereditary angioedema (HAE) in adults and pediatric patients 12 years of age and older. The condition causes frequent attacks of severe swelling in various parts of the body, including the hands, feet, genitals and face. Dawnzera will be available in the United States in the coming days with a list price of $57,462 per dose, the company said. HAE is estimated to affect about 7,000 patients in the U.S., according to Ionis. The drug, chemically known as donidalorsen, prevents HAE attacks by lowering levels of a protein called prekallikrein (PKK) that drives swelling and inflammation. Dawnzera can be self-administered through an under-the-skin injection once every four or eight weeks. The approval was supported by late-stage study results that showed the drug, dosed once every four weeks, reduced monthly attacks by 81% compared to a placebo over 24 weeks. Current FDA-approved therapies for HAE fall into two groups: prophylaxis to prevent attacks and on-demand medicines to treat acute attacks. Other approved prophylactic drugs include Takhzyro, developed by Japan’s Takeda Pharmaceutical and Haegarda from CSL (OTC:CSLLY) Behring. There is a lot of excitement for donidalorsen as patients who are not doing well on existing therapies have an option to switch to Dawnzera, which has a higher efficacy, TD Cowen analyst Yaron Werber said ahead of the approval. Takhzyro, given every two weeks, showed an average of 87% fewer attacks compared to a placebo over 6.5 months in a separate study involving adult and adolescent patients. Werber estimates peak annual sales of Ionis’ drug to be $509 million by 2032. ProPicks AI analyzes thousands of stocks using 100+ institutional-grade financial metrics to identify the strongest opportunities. With 80+ strategies across global markets, you might be surprised where IONS appears. Our flagship Tech Titans strategy doubled the S&P 500 within 18 months, including notable winners like Super Micro Computer (+185%) and AppLovin (+157%). Each strategy refreshes monthly with 10-20 high-conviction picks. Even if IONS isn't currently featured, you'll discover similar opportunities in the same industry or theme—stocks the AI identifies before they breakout. Now up to 50% off while our Summer Sale lasts.

Click Subscribe #FDAApproval #IonisPharmaceuticals #RareDiseases #GeneticDisorder #HealthNews

0 0 0 0

KStrategy&

@kstrategyand.bsky.social

1 year ago

Ionis' TRYNGOLZA™ Achieves FDA Milestone as First Treatment Option for Familial Chylomicronemia Syndrome Ionis Pharmaceuticals has achieved a groundbreaking milestone with the FDA approval of TRYNGOLZA™ (olezarsen), marking the first-ever treatment for adults with familial chylomicronemia syndrome (FCS)....

www.linkedin.com/pulse/ionis-...

Ionis' TRYNGOLZA™ Achieves FDA Milestone as First Treatment Option for Familial Chylomicronemia Syndrome

kstrategyand.com/pharma-news

#IonisPharmaceuticals #TRYNGOLZA #GeneticDisorders #LifeChangingTreatment #Humanteconomy #Humantec